FDA Inspection
Xellia Pharmaceuticals USA LLCXellia Pharmaceuticals USA LLC – FDA Inspection, Feb 7, 2022
Record Details
This FDA Inspection record concerns Xellia Pharmaceuticals USA LLC, with an inspection on February 7, 2022, issued by the Center for Drug Evaluation and Research, covering drugs.
- Inspection Date
- February 7, 2022
- Product Type
- Drugs
View Company Profile
ID · d429f017-a9d2-407b-a75e-05a5eb33faa5
Inspection Facts
Voluntary Action Indicated (VAI)
Objectionable conditions were found, but FDA is not prepared to take or recommend regulatory action.
- Inspection number
- 1161837
- FDA center
- Human Drugs
- Project area
- Drug Quality Assurance
FDA Citations
1- 21 CFR 211.22(d)Procedures not in writing, fully followed
Full citation text and observation details available on the Dashboard.
Other FDA inspections of Xellia Pharmaceuticals USA LLC
4| Date | Classification | Office | Project area |
|---|---|---|---|
| September 29, 2023 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| December 15, 2022 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| January 31, 2020 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| October 13, 2016 | NAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
Other documents for Xellia Pharmaceuticals USA LLC
- FDA Inspection 1220071 - 2023-09-29
- FDA Inspection 1194565 - 2022-12-15
- FDA Inspection 1117006 - 2020-01-31
- FDA Inspection 990058 - 2016-10-13
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.